Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

Studied

A randomized, blinded trial compared retatrutide with placebo for weight loss over 48 weeks.

Who / model

338 adults with obesity, or overweight plus a weight-related condition, participated.

Studied dose & schedule

Retatrutide target doses were 1, 4, 8 or 12 mg, given by subcutaneous injection once weekly for 48 weeks, versus placebo. The highest target dose was 12 mg. Higher-dose arms included different starting-dose groups.

Found

At 48 weeks, average weight loss was 24.2% in the highest-dose group versus 2.1% with placebo.

Limits

Digestive side effects were common and dose-related. Heart rate also increased with dose. These findings describe this trial's population and follow-up.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary